Clinical Trials Browser

NCT05263050 2026-05-22

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Phase 2 Recruiting

111 enrolled

EndocrineGenitourinaryNET

Clear-cell metastatic renal cell carcinoma, Carcinoid Tumor, Carcinoma, Renal Cell, Neuroendocrine Tumors

NCT05064514 2026-05-08

TRICAR

Phase NA Active not recruiting

15 enrolled

Endocrine

Carcinoid Heart Disease, Carcinoid Tumor, Tricuspid Valve Insufficiency, Serotonin Syndrome

NCT04907643 2026-02-20

Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

Phase NA Recruiting

360 enrolled

EndocrineGastrointestinalNET

Cancer Pain, Anus Neoplasms, Appendiceal Neoplasms, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoid Tumor, Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Liver Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Rectal Neoplasms, Recurrence, Stomach Neoplasms, Neuroendocrine Tumors, Visceral Pain

NCT04993261 2026-02-19

An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors

Phase EARLY_PHASE1 Active not recruiting

71 enrolled

Endocrine

Carcinoid Tumor, Serotonin Syndrome

NCT02826928 2026-01-21

Diagnostic Performances of Urine and Plasma 5-hydroxyindolacetic Acid (5HIAA) Values in Patients With Small-intestine Neuroendocrine Tumors

Phase NA Completed

116 enrolled

Endocrine

Carcinoid Tumor

NCT06790706 2025-10-06

IMMUNORARE5

Phase 2 Recruiting

154 enrolled

EndocrineGastrointestinalGynecologicHead & NeckNETThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Thymoma, Gestational Trophoblastic Disease, Thyroid Carcinoma, Anaplastic

NCT02795858 2025-02-19

A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors

Phase 2 Completed

43 enrolled 11 charts

Endocrine

Carcinoid Tumor

Clinical Trials

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

TRICAR

Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors

Diagnostic Performances of Urine and Plasma 5-hydroxyindolacetic Acid (5HIAA) Values in Patients With Small-intestine Neuroendocrine Tumors

IMMUNORARE5

A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors

Cabozantinib and Nivolumab for Carcinoid Tumors

P-PRRT

EVENET

Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors

Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers

Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres

Molecular-Guided Surgery for Pancreatic and GI Neuroendocrine Cancers

Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors

Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors

Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine Tumors

GA-68

Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors

RAD001 and Erlotinib in Patients With Neuroendocrine Tumors

Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

CHARRT

Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies

DOTA-TOC

A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors

A Study of Axitinib in Advanced Carcinoid Tumors

Clinic, Pathologic and Genetic Characterization of Patients With Familial Carcinoid Tumors (Study From the GTE, Groupe d'étude Des Tumeurs Endocrines)

Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion

AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)

A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

SUNLAND

Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma

Capecitabine and Temozolomide for Neuroendocrine Cancers

68Ga

Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors

Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors

Study of Panitumumab in the Treatment of Carcinoid Syndrome

Evaluation of Methods for the Determination of Chromogranin A in Routine Blood Samples

Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization

Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor